Stem cell industry hopes FDA will follow peptide approval path
Chuck Meeker and other stem cell advocates expect the FDA to hold roundtables on unapproved therapies before the end of 2026.
Peptide success drives stem cell hopes
Advocates believe the regulatory path for peptides will open doors for stem cells. Chuck Meeker told STAT that roundtables are likely to occur before year end. He views the current acceptance of compounded peptides as a signal for change.
Regulatory status remains different
While peptides gain tentative support, unapproved stem cell treatments have faced strict scrutiny. The FDA has not confirmed if upcoming meetings will happen soon. Industry leaders see this distinction as a temporary barrier rather than a permanent rule.
Goal is market expansion
Proponents want to move therapies from the grey market to mainstream availability. They aim to bring treatments to millions of Americans through new regulatory frameworks. This shift would align stem cell rules with recent peptide developments.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.